
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
about 3 years ago
Addressing the Clinical and Economic Impact of Heart Failureabout 3 years ago
Heart Failure Without a Reduced Ejection Fractionabout 3 years ago
Video Abstract: Heart Failure Without A Reduced Ejection Fractionabout 3 years ago
Defining a Path Toward Improved Heart Failure Careabout 3 years ago
Video Abstract: Defining a Path Toward Improved Heart Failure Care





